# A Study of Ixekizumab in Healthy Participants

> **NCT03848416** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 99 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** Ixekizumab

## Key facts

- **NCT ID:** NCT03848416
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-29
- **Primary completion:** 2019-06-07
- **Final completion:** 2019-06-07
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2020-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03848416

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03848416, "A Study of Ixekizumab in Healthy Participants". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03848416. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*